ArticleHemoglobin2026
SickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease.
Article in Hemoglobin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A qualitative evidence synthesis on perinatal screening for sickle cell disease in high-burden countries.BMC global and public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
Abstract
Sickle cell disease (SCD) remains a major public health concern in sub-Saharan Africa (SSA), where approximately 200,000 newborns are affected annually. Without early diagnosis and access to care, up to 50% of these children may die before the age of five. Although newborn screening (NBS) programs have proven effective in improving survival, their implementation across Africa is constrained by logistical barriers associated with standard diagnostic methods such as isoelectric focusing (IEF), high-performance liquid chromatography (HPLC), and cellulose acetate electrophoresis. Dried blood spot point-of-care testing (DBS-POCT) offers a potentially scalable alternative due to its stability, simplicity, and suitability for centralized analysis. We evaluated the diagnostic accuracy of DBS-POCT using the HemoTypeSC test compared to both standard POCT and reference laboratory testing across 705 newborns (0-3 months old) in seven countries within the SickleInAfrica Consortium. DBS-POCT demonstrated high sensitivity and specificity for detecting HbAA and HbAS, moderate sensitivity for HbSS, and lower sensitivity for HbAC, with some variability across countries. In several countries, DBS-POCT outperformed standard POCT, particularly in detecting SCD subtypes. Our findings support the utility of DBS-POCT for expanding newborn screening programs in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.